Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

22 results about "Isonicotinamide" patented technology

Isonicotinamide (pyridine-4-carboxamide) is the amide form of isonicotinic acid. It is an isomer of nicotinamide, which has the carboxamide group in the 3-position. It is soluble in water at 191 gm/L, also in ethanol, DMSO, methanol, chloroform, chloroform methanol mixture, and in dioxane 10 mg/L. This compound is used for material synthesis and is generally recognised as safe.

Continuous flow synthesis method for the manufacture of isoniazid

A multistep continuous flow synthesis method for the manufacture of isonicotinyl-hydrazide (Isoniazid) comprising reacting 4-cyano pyridine with NaOH at a specified molar ratio and temperature range to produce the intermediate isonicotinamide, which intermediate is reacted with hydrazine hydrate, without isolation thereof, at a specified molar ratio and temperature range to produce isonicotinyl-hydrazide (Isoniazid) in a yield greater than about 90%.
Owner:NELSON MANDELA METROPOLITAN UNIV

Robinin and isonicotinamide eutectic, preparation method, composition and application thereof

The invention discloses an acacetin and isonicotinamide eutectic, a preparation method, a composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention discloses an eutectic substance formed by acacetin and isonicotinamide, and the molecular formula of the eutectic substance is (C16H12O5). (C6H6N2O), the invention relates to a preparation method of a cocrystal of acacetin and isonicotinamide. The acacetin and isonicotinamide eutectic is used as an active ingredient of a medicine and is applied to preparation of medicines for resisting oxidation, resisting inflammation, resisting viruses, resisting tumors, resisting rheumatism, easing pain, protecting the liver, regulating immunity, treating osteoporosis and treating cardiovascular and cerebrovascular diseases.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI

Synthesis method of 2, 5-difluoro-4-cyanopyridine

The invention discloses a synthetic method of 2, 5-difluoro-4-cyanopyridine, and relates to the technical field of organic synthesis.The synthetic method comprises the following specific steps that S1, 2, 5-difluoropyridine and carbon dioxide are subjected to carbonyl synthesis reaction to obtain 2, 5-difluoropyridine-4-carboxylic acid; s2, the 2, 5-difluoropyridine-4-carboxylic acid, oxalyl chloride and ammonia water are subjected to a reaction, and 2, 5-difluoroisonicotinamide is obtained; and S3, enabling the 2, 5-difluoroisonicotinamide to react with trifluoroacetic anhydride, so as to obtain the 2, 5-difluoro-4-cyanopyridine. The method provided by the invention is simple in synthesis method, short in synthesis path and high in product yield.
Owner:NANTONG MINYAN BIOMEDICAL TECH CO LTD

Method for determining residual quantity of petroleum ether in icotinamide benzonate bulk drug by using capillary gas chromatography

The invention discloses a method for determining the residual quantity of petroleum ether in an isonicotinamide benzonate bulk drug by using capillary gas chromatography, and belongs to the technical field of drug analysis. According to the method, an external standard method is adopted for quantification, a 6% cyanopropyl phenyl-94% dimethyl polysiloxane capillary column is used as a chromatographic column, and an FID detector is adopted for detection; the residual quantity of the petroleum ether is the total residual quantity of normal hexane, 2-methylpentane and 3-methylpentane in the petroleum ether. The method disclosed by the invention is good in specificity, good in linearity, reliable in accuracy and high in sensitivity; the gas chromatographic method can be used for rapidly, effectively, accurately and reliably separating and detecting the residual amount of petroleum ether in the isopropylamine bulk drug, and is beneficial to improving the product quality of the isopropylamine bulk drug and improving the medication safety of a patient.
Owner:JIANGSU CIXING PHARM CO LTD

Co-crystal compounds comprising lithium ions and isonicotinamide

Stable crystal forms comprising lithium ions and the conjugate base of an organic acid which is in the form of anhydrous coordination polymer that exhibit improved in vivo performance with respect to lithium carbonate.
Owner:UNIVERSITY OF LIMERICK +1

A method for synthesizing chiral N-(4-chloro-2-(hydroxy(phenyl)methyl)phenyl)isonicotinamide

The invention provides a method for synthesizing chiral N-(4-chloro-2-(hydroxy(phenyl)methyl)phenyl)isonicotinamide (anti-inversion amine). The method uses N-(2-benzoyl-4-chlorophenyl)isonicotinamide as a raw material, uses a complex formed in situ by metal iridium and a phenylethylamine skeleton PNN ligand as a catalyst, methanol as a solvent, and potassium carbonate as an alkali additive. A hydrogenation reaction occurs under this homogeneous catalytic system, and N-(4-chloro-2-(hydroxy(phenyl)methyl)phenyl)isonicotinamide is obtained with a yield of >99% and an ee value of >99%. The method has high activity, mild conditions, and high industrial application value.
Owner:DALIAN INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES

Metal organic framework material as well as preparation method, application and separation method thereof

The invention provides a metal organic framework material as well as a preparation method, application and separation method thereof, and the metal organic framework material is prepared by dissolving metal cations, N, N '-(1, 4-phenylene) diisonicotinamide and an organic ligand in an organic solvent according to a molar ratio of 1: (0.1-2): (0.1-2) and then carrying out solvothermal reaction, the structural formula of the organic ligand is as follows: in the formula # imgabs0, R is one of H, CH3, NH2, F, Cl, Br and OH; amido and an R group are contained in a pore channel of the metal organic framework material. When the metal organic framework material is used as an adsorbent for separating carbon dioxide and nitrogen, efficient separation of carbon dioxide and nitrogen under a dry condition or a high-humidity condition, such as 75% RH moisture, can be realized.
Owner:PETROCHINA CO LTD

Method for preparing 2-propylthio-isonicotinamide intermediate through continuous pipeline

The invention is applied to the technical field of compound synthesis, and discloses a method for preparing a 2-propyl thio-isonicotinamide intermediate through a continuous pipeline, which comprises the following steps: dissolving 4-cyanopyridine and n-butyric acid in an organic solvent, and carrying out catalytic oxidation under the catalytic oxidation of silver nitrate and persulfate to obtain the 2-propyl thio-isonicotinamide intermediate. Meanwhile, alkaline water is used for controlling the pH value of a reaction system to synthesize the 2-propyl thio-isonicotinamide intermediate 2-propyl-4-cyanopyridine, and all the reactions are carried out in a pipeline reactor. 4-cyanopyridine and n-butyric acid are used as initial raw materials, persulfate and silver nitrate are used for oxidation catalysis to carry out free radical reaction, the reaction is carried out in a pipeline reactor, the yield is 95% or above, and the product purity is 99% or above; according to the pipeline continuous preparation method, by controlling the amount of each material entering the pipeline reactor in unit time, the reaction selectivity is improved, the generation of impurities is avoided, and the method is simple in process, convenient to operate, low in energy consumption, high in production efficiency, few in three wastes, simple in post-treatment and suitable for industrial production.
Owner:SUZHOU KAIYUAN MINSHENG SCI & TECH CORP

Crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer

The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl) isonicotinamide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl) isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.
Owner:NOVARTIS AG

Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer

The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.
Owner:NOVARTIS AG

A belinostat drug co-crystal and its preparation method and application

The present invention provides a belinostat drug cocrystal and a preparation method and application thereof, wherein the belinostat drug cocrystal is formed by combining a belinostat drug and a cocrystal ligand in a molar ratio of 1:1, and the cocrystal ligand is isoniazid or isonicotinamide; the method for preparing the drug cocrystal of the present invention is a solution-mediated method or a grinding method, and the two prepared belinostat cocrystals are characterized by means of X-ray powder diffraction (PXRD), single crystal X-ray powder diffraction (SXRD), differential scanning calorimetry (DSC), thermogravimetric analyzer (TGA), etc. The cocrystal of the present invention inherits the pharmacological activity of belinostat itself, and has obvious improvements in its solubility and stability.
Owner:TIANJIN UNIV

Dual synergistic nitrogen fertilizer inhibitor as well as preparation method and application thereof

The invention belongs to the technical field of nitrogen fertilizer inhibitors, and particularly relates to a dual synergistic nitrogen fertilizer inhibitor and a preparation method and application thereof, anhydrous copper nitrate, 2, 5-thiophenedicarboxylic acid and N, N '-(methylene bis (1, 4-phenyl)) diisonicotinamide are used as main components, and the main components are calcined in a reaction kettle to form the dual synergistic nitrogen fertilizer inhibitor. The dual synergistic nitrogen fertilizer inhibitor has the advantages of simple preparation method, high inhibition efficiency, good safety and the like, has better inhibition effect on urease activity, can denature and inactivate the structure of urease, delays the conversion from urea nitrogen to ammonium nitrogen, achieves the effect of inhibiting the urease activity, delays the conversion from ammonium nitrogen to nitrate nitrogen, and has good application prospects. The effect of inhibiting the activity of the nitrifying bacteria is achieved.
Owner:GUIZHOU TIANBAOFENG ORIGINAL ECOLOGY AGRI TECH LTD

Amorphous solid dispersions comprising natporafenib

The invention relates to the field of pharmacy, in particular to a pharmaceutical composition containing N (3-(2-(2-hydroxyethoxy)-6-morpholinopyridine-4-yl)-4-methylphenyl)-2-(trifluoromethyl) isonicotinamide or pharmaceutically acceptable salt of the N (3-(2-(2-hydroxyethoxy)-6-morpholinopyridine-4-yl)-4-methylphenyl)-2-(trifluoromethyl) isonicotinamide. The invention also provides methods for preparing the pharmaceutical compositions for oral administration and methods of treatment with the pharmaceutical compositions.
Owner:NOVARTIS AG

Rosmeltirol crystal form and preparation method thereof

The invention belongs to the technical field of crystal form medicine molecules, and particularly relates to a rosmeltirol crystal form and a preparation method thereof. The invention provides two crystal forms of rosmeltirol, and the crystal forms of rosmeltirol-nicotinamide-methanol have characteristic peaks at least at the positions of 6.2 + / -0.2 degrees, 14.4 + / -0.2 degrees, 21.5 + / -0.2 degrees, 22.4 + / -0.2 degrees, 24.3 + / -0.2 degrees, 26.5 + / -0.2 degrees and 27.4 + / -0.2 degrees in an X-ray diffraction spectrum represented by 2 theta by using Cu-K alpha radiation; according to the crystal form, Cu-K alpha radiation is used, and an X-ray diffraction spectrum represented by 2 theta has characteristic peaks at least at the positions of 12.0 + / -0.2 degrees, 15.6 + / -0.2 degrees, 17.8 + / -0.2 degrees, 19.9 + / -0.2 degrees, 20.8 + / -0.2 degrees and 28.1 + / -0.2 degrees. The rosmeltirol crystal form is good in stability, almost free of hygroscopicity, high in solubility and high in medicinal value.
Owner:LUNAN PHARMA GROUP CORPORATION

A zinc(ii)-calix[4]arene complex single crystal and a preparation method and application thereof

PendingCN122381356ASingle crystalCalixarene
The application discloses a zinc(II)-calix[4]arene complex single crystal and a preparation method and application thereof, and belongs to the technical field of coordination chemistry and adsorbents, and provides a preparation method of the zinc(II)-calix[4]arene complex single crystal, which comprises the following steps: mixing a soluble zinc source, 5,11,17,23-tetra[(m-carboxylphenyl)azo]-25,26,27,28-tetrahydroxycalix[4]arene and N-(pyridin-4-yl)isonicotinamide in a solvent, and reacting to obtain the zinc(II)-calix[4]arene complex single crystal. The zinc(II)-calix[4]arene complex single crystal prepared by the application has rich amide functional groups in a three-dimensional framework structure, and has rich active adsorption sites, and has good UO2 2+ adsorption removal effect.
Owner:YANTAI UNIV

Cocrystal compound of dihydromyricetin and preparation method thereof

The object of the present invention is to provide a new cocrystal compound of dihydromyricetin, which can increase its solubility, improve stability and improve bioavailability compared with dihydromyricetin, and the introduction of the cocrystal former can improve the crystallization performance and physicochemical properties of the drug itself. The present invention uses isonicotinamide or 4,4'-bipyridine as the cocrystal former, which interacts and combines in the unit cell through non-covalent bonds.
Owner:GUANGXI UNIV OF CHINESE MEDICINE

High-precision detection method for content of related substances in isoniazide injection

The invention provides a high-precision detection method for the content of related substances in an isoniazide injection. The content of four related substances including isonicotinamide, benzoyl hydrazine, 4-cyanopyridine and diisonicotinoyl hydrazine in the isoniazide injection can be accurately measured. The detection method comprises the following steps: S1, preparing a test solution and a mixed reference solution containing isoniazide and four related substances at the same time; s2, performing sample injection detection by using a high performance liquid chromatograph, performing sample injection mixing on the reference substance solution, and determining the retention time and the peak area of each related substance; and injecting the test solution, determining the peak appearance of each related substance according to the retention time, and calculating the content of each related substance through an external standard method. The detection method is high in sensitivity and durability, quantitative analysis can be carried out, the content of isoniazide, isonicotinamide, benzoyl hydrazine, 4-cyanopyridine and diisonicotinoyl hydrazine can be accurately detected, and a reasonable basis is provided for medicine quality control.
Owner:HEBEI LONGHAI PHARMA

Resmetirom crystal forms, preparation method therefor and use thereof

Provided in the present invention are a plurality of cocrystal forms of Resmetirom and isonicotinamide, a pharmaceutical composition containing the crystal forms, and the use of the crystal forms in the preparation of drugs for treating THR-β-mediated diseases.
Owner:QILU PHARMA CO LTD

Chrysin and isonicotinamide eutectic, preparation method, composition and application thereof

The invention discloses an eutectic substance formed by combining chrysin (English name: Chrysin) and isonicotinamide (English name: Isonicotinamide) through a non-covalent bond as well as a preparation method and application of the eutectic substance. Specifically, the invention discloses an eutectic substance formed by chrysin and isonicotinamide, and the molecular formula of the eutectic substance is C15H10O4. C6H6N2O, the invention relates to a preparation method of a chrysin and isonicotinamide eutectic. The chrysin and isonicotinamide eutectic is applied to preparation of medicines with the effects of preventing and treating cardiovascular diseases, resisting oxidation, resisting cancer, resisting virus, resisting hypertension, reducing blood fat, reducing blood sugar, resisting bacteria, diminishing inflammation and the like.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI

Amide-aluminum sulfate hydrated eutectic electrolyte for hydration treatment of high-voltage electrode foil and application of amide-aluminum sulfate hydrated eutectic electrolyte

The invention belongs to the technical field of aluminum foil formation, and discloses an amide-aluminum sulfate hydrated eutectic electrolyte for hydration treatment of a high-voltage electrode foil and application of the amide-aluminum sulfate hydrated eutectic electrolyte. The hydrated eutectic electrolyte is prepared by compounding aluminum sulfate and an amide compound (isonicotinamide, N-methyl nicotinamide or 2-pyrrolidone) according to a specific molar ratio, and the hydrated eutectic electrolyte is dissolved in high-purity water to form a stable eutectic system. Through the synergistic effect of the eutectic electrolyte, formation and densification of a hydration film (Al2O3.nH2O) on the surface of the aluminum foil are accelerated, and the technical problems that traditional hydration treatment is long in time (larger than or equal to 10 minutes), high in energy consumption, low in formation efficiency and multiple in oxidation film defect are solved. By applying the hydration treatment process, the hydration time can be shortened to 5-8 minutes, the formation efficiency is improved by 25-35%, the specific capacitance is improved by 1-5%, the leakage current is reduced by 15-25%, the energy consumption is reduced by 15-30%, the product quality and the production economy are remarkably improved, and the hydration treatment process is suitable for industrial production of the high-voltage electrode foil.
Owner:XINJIANG GUANGTOU GUIDONG ELECTRONICS TECH CO LTD +1